Specifically, hazard ratios (95% confidence intervals) of incident VTE were 1.27 (0.91-1.76), 1.06 (0.87-1.28), 1 (reference), 1.17 (0.98-1.40) and 1.72 (1.30-2.27) across the 5 hematocrit percentiles, adjusted for age, race, sex, body mass index, smoking status and pack-years, and other confounding variables. The association of high hematocrit…[Read more]

The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined.

Whole…[Read more]